Adamis Pharmaceuticals Corp Contracts & Agreements

COMMONSTOCK PURCHASE WARRANT ADAMISPHARMACEUTICALS CORPORATION (Filed With SEC on November 14, 2023)

ADAMIS PHARMACEUTICALSCORPORATION and EQUINITI TRUST COMPANY,LLC, as Warrant Agent WarrantAgency Agreement Dated as of August 4, 2023 WARRANT AGENCY AGREEMENT (Filed With SEC on November 14, 2023)

Employment Agreement between the Company and John W. Dorbin, Jr (Filed With SEC on November 14, 2023)

Employment Agreement between the Company and Seth A. Cohen (Filed With SEC on October 19, 2023)

Employment Agreement between the Company and John W. Dorbin, Jr (Filed With SEC on October 19, 2023)

Inducement Stock Option Award Agreement dated as of October 16, 2023 (Filed With SEC on October 19, 2023)

Form of Inducement Stock Option Award Agreement (Filed With SEC on October 19, 2023)

Executive Employment Agreement between the Company and Ebrahim Versi dated as of August 23, 2023 (Filed With SEC on August 29, 2023)

Placement Agency Agreement (Filed With SEC on August 3, 2023)

Securities Purchase Agreement (Filed With SEC on August 3, 2023)

Purchase and Sale Agreement (Filed With SEC on July 24, 2023)

Sales Agreement (Filed With SEC on July 24, 2023)

Form of Placement Agent Agreement (Filed With SEC on July 13, 2023)

Form of Common Stock Warrant (Filed With SEC on July 13, 2023)

Form of Pre-Funded Warrant (Filed With SEC on July 13, 2023)

Form of Warrant Agency Agreement (Filed With SEC on July 13, 2023)

Form of Securities Purchase Agreement (Filed With SEC on July 13, 2023)

Letter dated May 24, 2023, between the Company and David J. Marguglio (Filed With SEC on May 26, 2023)

Offer letter dated May 24, 2023, between the Company and Ebrahim Versi, M.D., Ph.D (Filed With SEC on May 26, 2023)

DMK 2016 Stock Plan (Filed With SEC on May 26, 2023)

Common Stock Purchase Warrant dated March 16, 2023 (Filed With SEC on May 15, 2023)

Prefunded Common Stock Purchase Warrant dated March 16, 2023 (Filed With SEC on May 15, 2023)

Securities Purchase Agreement dated March 14, 2023 (Filed With SEC on May 15, 2023)

Support Agreement dated February 24, 2023 (Filed With SEC on May 15, 2023)

Form of Indemnity Agreement with Directors and Executive Officers (Filed With SEC on May 15, 2023)

Form of Common Stock Purchase Warrant (Filed With SEC on March 14, 2023)

Form of Prefunded Common Stock Purchase Warrant (Filed With SEC on March 14, 2023)

Form of Securities Purchase Agreement (Filed With SEC on March 14, 2023)

Agreement and Plan of Merger and Reorganization, dated as of February 24, 2023, by and among Adamis Pharmaceuticals, Inc., Adamis Merger Sub, Inc., and DMK Pharmaceuticals... (Filed With SEC on February 27, 2023)

Form of Support Agreement, dated February 24, 2023, by and among Adamis Pharmaceuticals, Inc., Aardvark Merger Sub, Inc., DMK Pharmaceuticals Corporation, and certain stockholders... (Filed With SEC on February 27, 2023)

Common Stock Purchase Warrant dated July 5, 2022 (Filed With SEC on July 6, 2022)

Securities Purchase Agreement, dated July 5, 2022, between Adamis Pharmaceuticals Corporation and the parties thereto (Filed With SEC on July 6, 2022)

Registration Rights Agreement, dated July 5, 2022, between Adamis Pharmaceuticals Corporation and the parties thereto (Filed With SEC on July 6, 2022)

Executive Employment Agreement between the Company and David C. Benedicto dated as of June 22, 2022 (Filed With SEC on June 24, 2022)

Press Release issued May 26, 2022 (Filed With SEC on May 26, 2022)

Separation Agreement and Release dated as of May 18, 2022 (Filed With SEC on May 19, 2022)

Executive Employment Agreement between the Company and David J. Marguglio dated as of May 18, 2022 (Filed With SEC on May 19, 2022)

First Amendment to Exclusive License Agreement dated November 9, 2021 between the Company and Matrix Biomed, Inc (Filed With SEC on March 31, 2022)

Settlement Agreement between the Company, US Compounding Inc., Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., Nephron Sterile Compounding Center, LLC and certain other... (Filed With SEC on November 22, 2021)

Press Release dated October 4, 2021 (Filed With SEC on October 4, 2021)

Asset Purchase Agreement effective as of July 30, 2021, by and among the Registrant, US Compounding, Inc. and Fagron Compounding Services, LLC (Filed With SEC on August 5, 2021)

Supply Agreement Addendum by and among the Registrant, US Compounding, Inc. and Fagron Compounding Services, LLC (Filed With SEC on August 5, 2021)

Description of the Registrant's Capital Stock (Filed With SEC on April 15, 2021)

Lease Agreement between the Company and Oil States Energy Services, LLC, as amended (Filed With SEC on April 15, 2021)

Promissory Note dated March 15, 2021 (Filed With SEC on April 15, 2021)

Underwriting Agreement, dated January 29, 2021, by and between Adamis Pharmaceuticals Corporation and Raymond James & Associates, Inc., as representative of the underwriters named... (Filed With SEC on January 29, 2021)

Underwriting Agreement, dated September 18, 2020, by and between Adamis Pharmaceuticals Corporation and Raymond James & Associates, Inc., as representative of the underwriters... (Filed With SEC on September 18, 2020)

August 2020 Amendment to Loan Amendment and Assumption Agreement between the Company and Arvest Bank (Filed With SEC on September 15, 2020)

Amended Promissory Note between the Company and Arvest Bank (Filed With SEC on September 15, 2020)

2020 Equity Incentive Plan (Filed With SEC on August 24, 2020)

*** Certain identified information hasbeen omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrantif publicly... (Filed With SEC on August 17, 2020)

Distribution and Commercialization Agreement between the Company and USWM, LLC (Filed With SEC on August 17, 2020)

Description of the Registrants Common Stock (Filed With SEC on June 22, 2020)

Adamis Pharmaceuticals Corporation 2020 Bonus Plan (Filed With SEC on June 22, 2020)

Promissory Note date April 10, 2020 (Filed With SEC on April 15, 2020)

DESCRIPTION OF CAPITAL STOCK (Filed With SEC on March 30, 2020)

Form of Warrant (Filed With SEC on February 21, 2020)

Form of Securities Purchase Agreement (Filed With SEC on February 21, 2020)

Placement Agency Agreement (Filed With SEC on February 21, 2020)

Form of Warrant dated August 5, 2019 (Filed With SEC on November 12, 2019)

Form of Stock Appreciation Rights Agreement for Non-Employee Directors (Filed With SEC on November 12, 2019)

Underwriting Agreement, dated August 1, 2019, by and between Adamis Pharmaceuticals Corporation and Raymond James & Associates, Inc., as representative of the underwriters named... (Filed With SEC on August 1, 2019)

Form of Warrant (Filed With SEC on August 1, 2019)

Adamis Pharmaceuticals Corporation 2019 Bonus Plan (Filed With SEC on February 5, 2019)

Distribution and Commercialization Agreement between the Company and Sandoz, Inc (Filed With SEC on November 9, 2018)

June 2018 Amendment to Loan and Security Agreement (Filed With SEC on August 9, 2018)

Underwriting Agreement (Filed With SEC on August 2, 2018)

March 2018 Amendment to Loan and Security Agreement (Filed With SEC on March 16, 2018)

March 2018 Amended and Restated Line of Credit Promissory Note (Filed With SEC on March 16, 2018)

Adamis Pharmaceuticals Corporation 2018 Bonus Plan (Filed With SEC on February 27, 2018)

Description of Compensation Committee Authorization Regarding Discretionary Compensation Payments (Filed With SEC on February 27, 2018)

Form of Warrant Repricing Letter Agreement (Filed With SEC on August 21, 2017)

Form of Warrant Repricing Letter Agreement (Filed With SEC on July 20, 2017)

Underwriting Agreement (Filed With SEC on April 21, 2017)

Form of Restricted Stock Unit Agreement (Filed With SEC on March 30, 2017)

Loan Amendment and Assumption Agreement and related Agreements and Instruments dated as of November 3, 2016 (Filed With SEC on March 30, 2017)

September 2016 Loan Amendment and Consolidation Agreement among Bear State Bank, N.A., U.S. Compounding, Inc., Tribute Labs, LLC, and the Company (Filed With SEC on March 30, 2017)

Amendment to Loan Agreement dated as November 3, 2016 between Bear State Bank, N.A., and the Company (Filed With SEC on March 30, 2017)

September 2016 Amendment to Commercial Line of Credit Agreement and Note (Filed With SEC on March 30, 2017)

Loan Release Agreement dated as of November 14, 2016 (Filed With SEC on March 30, 2017)

2017 Bonus Plan (Filed With SEC on March 30, 2017)

Executive Employment Agreement between the Company and Eddie W. Glover dated March 28, 2016 (Filed With SEC on March 30, 2017)

Executive Employment Agreement between the Company and Ronald B. Moss, M.D., dated as of February 28, 2017 (Filed With SEC on March 30, 2017)

March 2017 Amended and Restated Line of Credit Promissory Note (Filed With SEC on March 30, 2017)

March 2017 Amendment to Loan and Security Agreement between the Company and Bear State Bank (Filed With SEC on March 30, 2017)

Adamis Pharmaceuticals Corporation 2017 Bonus Plan (Filed With SEC on January 11, 2017)

Business Loan Agreement dated July 14, 2014, between First Federal Bank and U.S. Compounding, Inc., and related loan documents (Filed With SEC on August 15, 2016)

Business Loan Agreement between 4 HIMS, LLC and First Federal Bank dated August 8, 2014, and related loan documents (Filed With SEC on August 15, 2016)

Business Loan Agreement between Tribute Labs, LLC and First Federal Bank dated March 21, 2014, and related loan documents (Filed With SEC on August 15, 2016)

Loan Amendment, Forbearance and Assumption Agreement, between the Company and Bear State Bank, N.A (Filed With SEC on August 15, 2016)

Development, License and Commercialization Agreement dated as of May [10], 2016, between the Company and Watson Laboratories, Inc (Filed With SEC on August 15, 2016)

[*Designatesportions of this document have been omitted pursuant to a request for confidential treatment filed separately with the Commission] DEVELOPMENT,LICENSE AND... (Filed With SEC on August 15, 2016)

Form of Warrant dated July 29, 2016 (Filed With SEC on July 29, 2016)

Placement Agency Agreement dated July 29, 2016 (Filed With SEC on July 29, 2016)

Form of Securities Purchase Agreement dated July 29, 2016 (Filed With SEC on July 29, 2016)

Purchase Agreement dated as of July 11, 2016 (Filed With SEC on July 12, 2016)

Registration Rights Agreement dated July 11, 2016 (Filed With SEC on July 12, 2016)

Form of Warrant dated July 11, 2016 (Filed With SEC on July 12, 2016)

Agreement and Plan of Merger, dated as of March 28, 2016, by and among the Company, US Compounding, Inc., Ursula MergerSub Corp., and Eddie Glover, as Stockholders Representative (Filed With SEC on March 29, 2016)

Form of Joinder Agreement, dated as of March 28, 2016, by and between the Company and certain stockholders of U.S. Compounding, Inc (Filed With SEC on March 29, 2016)

Loan and Security Agreementby and between Adamis Pharmaceuticals Corporation and Bear State Bank, N.A (Filed With SEC on March 29, 2016)

Warrant dated March 28, 2016 (Filed With SEC on March 29, 2016)

Executive Employment Agreement between the Company and Dennis J. Carlo dated December 31, 2015 (Filed With SEC on March 23, 2016)

Executive Employment Agreement between the Company and David J. Marguglio dated December 31, 2015 (Filed With SEC on March 23, 2016)

Executive Employment Agreement between the Company and Robert O. Hopkins dated December 31, 2015 (Filed With SEC on March 23, 2016)

Executive Employment Agreement between the Company and Karen K. Daniels dated December 31, 2015 (Filed With SEC on March 23, 2016)

Executive Employment Agreement between the Company and Thomas H. Moll,Ph.D. dated December 31, 2015 (Filed With SEC on March 23, 2016)

Adamis Pharmaceuticals Corporation 2016 Bonus Plan (Filed With SEC on March 14, 2016)

Form of Warrant dated January 26, 2016 (Filed With SEC on January 26, 2016)

Form of Amended and Restated Warrant dated January 26, 2016 (Filed With SEC on January 26, 2016)

Purchase Agreement dated as of January 26, 2016 (Filed With SEC on January 26, 2016)

Amended and Restated Registration Rights Agreement dated January 26, 2016 (Filed With SEC on January 26, 2016)

MANUFACTURING AGREEMENT Adamis APC-5000 Dry Powder Inhaler and other Related Products (Filed With SEC on August 7, 2015)

ADAMIS PHARMACEUTICALS CORPORATION 2015 BONUS PLAN (Filed With SEC on March 11, 2015)

Underwriting Agreement (Filed With SEC on January 9, 2015)

2009 Equity Incentive Plan (Filed With SEC on November 14, 2014)

Form of Warrants dated June 26, 2013 (Filed With SEC on November 14, 2014)

Form of Warrant dated August 19, 2014 (Filed With SEC on August 20, 2014)

Purchase Agreement dated as of August 19, 2014 (Filed With SEC on August 20, 2014)

Registration Rights Agreement dated August 19, 2014 (Filed With SEC on August 20, 2014)

OFFICELEASE AGREEMENT BETWEEN PACIFICNORTH COURT HOLDINGS, L.P., ASLANDLORD AND ADAMISPHARMACEUTICALS CORPORATION ASTENANT (Filed With SEC on June 23, 2014)

Amendment to Convertible Promissory Note dated March 26, 2014 (Filed With SEC on April 1, 2014)

Sublease dated as of February 1, 2014 between the Registrant and McDermott Will & Emery LLP (Filed With SEC on February 14, 2014)

3,720,000 Shares Adamis Pharmaceuticals Corporation PURCHASE AGREEMENT (Filed With SEC on December 17, 2013)

3,100,000Shares AdamisPharmaceuticals Corporation PURCHASEAGREEMENT (Filed With SEC on December 10, 2013)

Form of Representative’sWarrant Agreement (Filed With SEC on December 10, 2013)

SUBLEASE (Filed With SEC on November 15, 2013)

Consent and Waiver (Filed With SEC on October 31, 2013)

Exclusive License and Asset Purchase Agreement dated as of August 1, 2013, by and among the Company, 3M Corp. and 3M Innovative Properties Company (Filed With SEC on August 6, 2013)

Subscription Agreement dated as of June 26, 2013 (Filed With SEC on July 2, 2013)

Form of Secured Convertible Notes dated June 26, 2013 (Filed With SEC on July 2, 2013)

Escrow Agreement dated June 26, 2013 (Filed With SEC on July 2, 2013)

Security Agreement dated June 26, 2013 (Filed With SEC on July 2, 2013)

Intercreditor Agreement dated June 26, 2013 (Filed With SEC on July 2, 2013)

Securities Purchase Agreement dated as of April 5, 2013 (Filed With SEC on April 8, 2013)

Form of 12% Convertible Debenture dated April 5, 2013 (Filed With SEC on April 8, 2013)

Zero Coupon Secured Promissory Note dated October 25, 2012 (Filed With SEC on February 19, 2013)

Convertible Promissory Note dated December 31, 2012 (Filed With SEC on February 19, 2013)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on July 6, 2012)

Securities Purchase Agreement dated as of June 11, 2012 (Filed With SEC on June 15, 2012)

10% Senior Convertible Note dated as of June 11, 2012 (Filed With SEC on June 15, 2012)

Form of Subsidiary Guarantee dated as of June 11, 2012 (Filed With SEC on June 15, 2012)

Convertible Promissory Note dated as of June 11, 2012 (Filed With SEC on June 15, 2012)

Securities Purchase Agreement dated as of April 2, 2012 (Filed With SEC on April 5, 2012)

10% Senior Convertible Note dated as of April 2, 2012 (Filed With SEC on April 5, 2012)

Form of Subsidiary Guarantee dated as of April 2, 2012 (Filed With SEC on April 5, 2012)

Third Amendment to Common Stock Purchase Agreement dated as of January 31, 2012, by and between the Company and Eses Holdings (FZE) (Filed With SEC on February 14, 2012)

THIRD AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on February 6, 2012)

Second Amendment to Common Stock Purchase Agreement dated as of November 10, 2011, by and between the Company and Eses Holdings (FZE) (Filed With SEC on November 21, 2011)

Form of Stock Option Agreement for option awards (Filed With SEC on September 16, 2011)

License Agreement between Adamis, the Regents of the University of California and Dana-Farber Cancer Institute, Inc (Filed With SEC on July 7, 2011)

License Agreement dated January 26, 2007, with Wisconsin Alumni Research Foundation (Filed With SEC on July 7, 2011)

License Agreement dated January 2, 2008, with Wisconsin Alumni Research Foundation (Filed With SEC on July 7, 2011)

First Amendment to Common Stock Purchase Agreement dated as of June 30, 2011, by and between the Company and Eses Holdings (FZE) (Filed With SEC on July 7, 2011)

AMENDMENT TO ADAMIS PHARMACEUTICALS CORPORATION 10% SENIOR SECURED CONVERTIBLE NOTE (Filed With SEC on April 4, 2011)

AMENDMENT TO ADAMIS PHARMACEUTICALS CORPORATION CONVERTIBLE PROMISSORY NOTE (Filed With SEC on April 4, 2011)

PRODUCT DEVELOPMENT & CONTRACT MANUFACTURING AGREEMENT Adamis Pharmaceuticals Corp., USA and Beximco Pharmaceuticals Ltd., Bangladesh (Filed With SEC on February 14, 2011)

Form of Option Agreement for Non-Employee Directors (Filed With SEC on January 13, 2011)

Form of Director and Officer Indemnity Agreement (Filed With SEC on January 13, 2011)

2009 Equity Incentive Plan (Filed With SEC on January 13, 2011)

Form of Amendment to 10% Senior Secured Convertible Notes (Filed With SEC on December 10, 2010)

Amendment to G-Max Convertible Promissory Note (Filed With SEC on December 10, 2010)

Common Stock Purchase Agreement dated as of November 10, 2010, by and between Adamis Pharmaceuticals Corporation and the Purchaser named therein. (Confidential treatment has been... (Filed With SEC on November 12, 2010)

Registration Rights Agreement dated as of November 10, 2010, by and between Adamis Pharmaceuticals Corporation and the Purchaser named therein (Filed With SEC on November 12, 2010)

Employment Agreement between the Company and Dennis J. Carlo (Filed With SEC on November 12, 2010)

Employment Agreement between the Company and David J. Marguglio (Filed With SEC on November 12, 2010)

Employment Agreement between the Company and Robert O. Hopkins (Filed With SEC on November 12, 2010)

Employment Agreement between the Company and Richard L. Aloi (Filed With SEC on November 12, 2010)

Amendment to Assignment, Assumption and Stock Acquisition Agreement (Filed With SEC on October 19, 2010)

ASSIGNMENT, ASSUMPTION AND STOCK ACQUISITION AGREEMENT (Filed With SEC on July 14, 2010)

Letter of Termination of Merger Agreement dated March 3, 2010 (Filed With SEC on March 4, 2010)

Securities Purchase Agreement dated as of January 11, 2010 (Filed With SEC on January 15, 2010)

10% Senior Secured Convertible Note dated as of January 11, 2010 (Filed With SEC on January 15, 2010)

Security Agreement dated as of January 11, 2010 (Filed With SEC on January 15, 2010)

Form of Lock-Up Agreement (Filed With SEC on January 15, 2010)

Subsidiary Guarantee Agreement dated as of January 11, 2010 (Filed With SEC on January 15, 2010)

Convertible Promissory Noted dated December 29, 2009 (Filed With SEC on January 4, 2010)

Agreement and Plan of Reorganization, by and among La Jolla Pharmaceutical Company, Adamis Pharmaceuticals Corporation and Jewel Merger Sub, Inc., dated as of December 4, 2009 (Filed With SEC on December 7, 2009)

ADAMISPHARMACEUTICALS CORPORATION 2009EQUITY INCENTIVE PLAN (Filed With SEC on August 19, 2009)

ADAMISPHARMACEUTICALS CORPORATION 2009EQUITY INCENTIVE PLAN (Filed With SEC on April 3, 2009)

ADAMISPHARMACEUTICALS CORPORATION STOCKOPTION GRANT NOTICE INITIALGRANT 2009EQUITY INCENTIVE PLAN (Filed With SEC on April 3, 2009)

CellegyPharmaceuticals, Inc. 125Grandview road Boyertown,PA 19512 (Filed With SEC on January 8, 2009)

Cellegy Pharmaceuticals, Inc. 125 Grandview road Boyertown, PA 19512 (Filed With SEC on November 13, 2008)

VOTING AGREEMENT (Filed With SEC on November 13, 2008)

AGREEMENT AND PLAN OF REORGANIZATION between CELLEGY PHARMACEUTICALS, INC., a Delaware corporation, CELLEGY HOLDINGS, INC. a Delaware corporation and ADAMIS PHARMACEUTICALS... (Filed With SEC on February 13, 2008)

VOTING AGREEMENT (Filed With SEC on February 13, 2008)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on February 13, 2008)

LICENSE AGREEMENT between CONRAD, Eastern Virginia Medical School and Biosyn, Inc., a subsidiary of Cellegy Pharmaceuticals, Inc. (Filed With SEC on April 2, 2007)

PROMISSORY NOTE U.S.$2,000,000 Dated as of: September 26, 2006 (Filed With SEC on November 14, 2006)

PATENT COLLATERAL ASSIGNMENT AND SECURITY AGREEMENT (Filed With SEC on November 14, 2006)

SHARE PURCHASE AGREEMENT (Filed With SEC on August 10, 2006)

CELLEGY PHARMACEUTICALS, INC. 2005 EQUITYINCENTIVEPLAN Adopted June 8, 2005 (Filed With SEC on March 31, 2006)

CELLEGY PHARMACEUTICALS,INC. 2005 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (Filed With SEC on March 31, 2006)

FIRST AMENDED AND RESTATED EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT FOR RECTOGESIC Between STRAKAN INTERNATIONAL LIMITED And Cellegy Pharmaceuticals, Inc. Confidential (Filed With SEC on March 31, 2006)

First Amended and Restated Exclusive License Agreement For Tostrex Between STRAKAN INTERNATIONAL LIMITED And Cellegy Pharmaceuticals, Inc. Confidential (Filed With SEC on March 31, 2006)

CELLEGY PHARMACEUTICALS, INC. SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Filed With SEC on May 16, 2005)

CELLEGYPHARMACEUTICALS, INC. SERIES BWARRANT TO PURCHASE SHARES OF COMMONSTOCK, PAR VALUE $0.0001 PER SHARE (Filed With SEC on May 16, 2005)

PURCHASEAGREEMENT (Filed With SEC on May 16, 2005)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 16, 2005)

SUBLEASE Sublessor: VAXGEN, INC., a Delaware corporation Sublessee: CELLEGY PHARMACEUTICALS, INC., a Delaware corporation Premises Located at: 1000 Marina Blvd., Ste. 300... (Filed With SEC on March 31, 2005)

EXCLUSIVELICENSE AND DISTRIBUTION AGREEMENT FOR RECTOGESIC BETWEEN STRAKANINTERNATIONAL LIMITED AND CELLEGYPHARMACEUTICALS, INC. CONFIDENTIAL (Filed With SEC on March 31, 2005)

AGREEMENT DATED AS OF OCTOBER 8, 1996 BY AND AMONG BIOSYN, INC., EDWIN B. MICHAELS AND E.B.MICHAELS RESEARCH ASSOCIATES, INC. 1 (Filed With SEC on March 31, 2005)

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENTEXCLUSIVE COVER PAGE (Filed With SEC on March 31, 2005)

LICENSE AGREEMENT between CROMPTON CORPORATION and BIOSYN, INC. (Filed With SEC on March 31, 2005)

BIOSYN, INC. 1999 STOCK OPTION PLAN (as amended effective October 7, 2004) (Filed With SEC on November 12, 2004)

CELLEGY PHARMACEUTICALS, INC. STOCK OPTION ASSUMPTION AGREEMENT (Non-Plan Options) (Filed With SEC on November 12, 2004)

CELLEGY PHARMACEUTICALS, INC. STOCK OPTION ASSUMPTION AGREEMENT (1999 Stock Option Plan) (Filed With SEC on November 12, 2004)

CELLEGY PHARMACEUTICALS, INC. NOTICE OF ASSUMPTION OF BIOSYN OPTIONS (Filed With SEC on November 12, 2004)

AGREEMENT AND PLAN OF SHARE EXCHANGE between CELLEGY PHARMACEUTICALS, INC. and BIOSYN, INC. a Pennsylvania corporation Dated as of October 7, 2004 (Filed With SEC on October 26, 2004)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 26, 2004)

AGREEMENT AND PLAN OF MERGER AND REINCORPORATION (Filed With SEC on September 3, 2004)

EXCLUSIVE LICENSE AGREEMENT FOR TOSTREX BETWEEN STRAKAN INTERNATIONAL LIMITED AND CELLEGY PHARMACEUTICALS, INC. CONFIDENTIAL (Filed With SEC on August 10, 2004)

Category

Industry

Companies

Contracts

Adamis Pharmaceuticals Corp Contracts & Agreements